Recurrence or progression of cancer occurred in 51/339 (15%) women, comprising 14% of those with MMR‐D, 8% of those with POLE EDM, 9% of those with p53 wt and 45% of those with p53 abn ProMisE subtype. Here, TP53 is linked to cancer.